Angiotech Pharmaceuticals (ANP) Inactive 10-Q2010 Q2 Quarterly report

Filed: 9 Aug 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: ABI, absolute, allergic, alter, ascribed, awaiting, baseline, consecutive, cumulative, decided, dental, department, earliest, Encompassing, endovascular, explaining, forma, frame, function, functional, grace, inducement, infusional, lack, landlord, leasehold, left, LVEF, microsurgical, necessitating, Nineteen, nitinol, patency, payroll, PCR, pro, regain, rent, tied, ventricular, vital, whetherthe, wind, WrapTM

Removed: acceptable, angiography, assume, attractive, began, budgeted, candidate, Cardiology, collaborative, collectively, College, combined, complementary, damage, diameter, endpoint, enforcing, excluding, exclusion, exert, expensed, forced, half, harm, healing, historic, historically, lead, Leaf, marketplace, met, mm, novo, postponed, pressure, profitability, profitable, profitably, prosecuting, realize, recent, recently, record, refinance, regulation, repay, responsibility, showing, staffing, stem, TLR, trend, Trust, turn, unprofitable, vary, workhorse, worse, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ANP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

Certification of CEO and CFO Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned, the Chief Executive Officer and the Chief Financial Officer of Angiotech Pharmaceuticals, Inc. (the “Company”), each hereby certifies that to his knowledge on the date hereof:

(a)	The Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2010, filed on the date hereof with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)	Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 9, 2010				/s/ William L. Hunter
				William L. Hunter, M.D.
				Chief Executive Officer

Date: August 9, 2010				/s/ K. Thomas Bailey
				K. Thomas Bailey
				Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.